Sickle Cell Disease (SCD) Emerging Therapy and TPP Insights

Thelansis’s “Sickle Cell Disease (SCD) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Sickle Cell Disease (SCD) Overview

Sickle cell disease (SCD) is an autosomal recessive hemoglobinopathy caused by a glutamic acid to valine substitution at position 6 of the beta-globin chain, yielding abnormal hemoglobin S that polymerizes under deoxygenated conditions to drive erythrocyte sickling, hemolytic anemia, and vaso-occlusion. Hallmarks include severe episodic vaso-occlusive crises (VOCs), acute chest syndrome, stroke, and cumulative multiorgan damage. Diagnosis is established via universal newborn screening using hemoglobin electrophoresis or HPLC. Hydroxyurea remains the foundational oral disease-modifying standard of care to elevate fetal hemoglobin, supplemented by oral L-glutamine to reduce oxidative stress. Crucially, the pharmaceutical toolkit has contracted significantly due to safety and efficacy failures: both the polymerization inhibitor voxelotor and the P-selectin inhibitor crizanlizumab have been completely withdrawn from global markets. Conversely, the curative space has been fundamentally transformed. Alongside traditional matched allogeneic stem cell transplantation, two landmark genetic therapies are approved for severe phenotypes: lovotibeglogene autotemcel (Lyfgenia), a lentiviral gene-addition therapy, and exagamglogene autotemcel (Casgevy), a CRISPR-Cas9 gene-editing platform targeting BCL11A to restore functional fetal hemoglobin. These molecular therapies yield near-complete elimination of VOCs, radically rewriting the long-term prognosis.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)